Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Dr Reddy’s Laboratories ( (RDY) ) just unveiled an announcement.
Dr. Reddy’s Laboratories has notified stock exchanges that its management will meet analysts and institutional investors at two upcoming conferences in early March 2026. The company will join an in-person group meeting hosted by Ambit Capital in Hyderabad on March 4, 2026, followed by a virtual group meeting organized by Goldman Sachs on March 5, 2026.
The announced investor interactions form part of Dr. Reddy’s regular engagement with the financial community and may help reinforce its visibility among domestic and global institutions. The company cautioned that the schedule could change due to exigencies on the part of either investors or the company, underscoring the indicative nature of the planned meetings.
The most recent analyst rating on (RDY) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.
Spark’s Take on RDY Stock
According to Spark, TipRanks’ AI Analyst, RDY is a Outperform.
The score is driven primarily by strong fundamentals (profitability, growth, and low leverage), tempered by weaker cash-flow conversion. Earnings-call takeaways are moderately positive due to pipeline progress and strong liquidity, but near-term margins and regulatory delays add risk. Technicals are neutral-to-soft and valuation is reasonable with a low dividend yield.
To see Spark’s full report on RDY stock, click here.
More about Dr Reddy’s Laboratories
Dr. Reddy’s Laboratories is an India-based global pharmaceutical company focused on generic medicines, active pharmaceutical ingredients and branded formulations. Listed in India and on the New York Stock Exchange, the company serves regulated markets worldwide, positioning itself as a key player in affordable healthcare and specialty therapies.
Average Trading Volume: 1,574,811
Technical Sentiment Signal: Strong Buy
Current Market Cap: $11.93B
For detailed information about RDY stock, go to TipRanks’ Stock Analysis page.